134 related articles for article (PubMed ID: 11139317)
1. CD55 is over-expressed in the tumour environment.
Li L; Spendlove I; Morgan J; Durrant LG
Br J Cancer; 2001 Jan; 84(1):80-6. PubMed ID: 11139317
[TBL] [Abstract][Full Text] [Related]
2. Decay accelerating factor (CD55): a target for cancer vaccines?
Spendlove I; Li L; Carmichael J; Durrant LG
Cancer Res; 1999 May; 59(10):2282-6. PubMed ID: 10344729
[TBL] [Abstract][Full Text] [Related]
3. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.
Ravindranath NM; Shuler C
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Feb; 103(2):231-9. PubMed ID: 17234541
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy.
Bjørge L; Stoiber H; Dierich MP; Meri S
Scand J Immunol; 2006 May; 63(5):355-64. PubMed ID: 16640659
[TBL] [Abstract][Full Text] [Related]
5. The role of CD55 in protecting the tumour environment from complement attack.
Morgan J; Spendlove I; Durrant LG
Tissue Antigens; 2002 Sep; 60(3):213-23. PubMed ID: 12445304
[TBL] [Abstract][Full Text] [Related]
6. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas.
Mashino K; Sadanaga N; Tanaka F; Yamaguchi H; Nagashima H; Inoue H; Sugimachi K; Mori M
Br J Cancer; 2001 Sep; 85(5):713-20. PubMed ID: 11531257
[TBL] [Abstract][Full Text] [Related]
7. Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer.
Levy EM; Bianchini M; Von Euw EM; Barrio MM; Bravo AI; Furman D; Domenichini E; Macagno C; Pinsky V; Zucchini C; Valvassori L; Mordoh J
Int J Oncol; 2008 Mar; 32(3):633-41. PubMed ID: 18292941
[TBL] [Abstract][Full Text] [Related]
8. Expression of complement restriction factors (CD46, CD55 & CD59) in head and neck squamous cell carcinomas.
Ravindranath NM; Shuler C
J Oral Pathol Med; 2006 Oct; 35(9):560-7. PubMed ID: 16968237
[TBL] [Abstract][Full Text] [Related]
9. A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.
Ullenhag GJ; Spendlove I; Watson NF; Indar AA; Dube M; Robins RA; Maxwell-Armstrong C; Scholefield JH; Durrant LG
Clin Cancer Res; 2006 Dec; 12(24):7389-96. PubMed ID: 17121873
[TBL] [Abstract][Full Text] [Related]
10. Tumour endothelial marker 8 (TEM-8) in human colon cancer and its association with tumour progression.
Rmali KA; Watkins G; Harrison G; Parr C; Puntis MC; Jiang WG
Eur J Surg Oncol; 2004 Nov; 30(9):948-53. PubMed ID: 15498639
[TBL] [Abstract][Full Text] [Related]
11. Characterization of novel CD55 isoforms expression in normal and neoplastic tissues.
Vainer ED; Meir K; Furman M; Semenenko I; Konikoff F; Vainer GW
Tissue Antigens; 2013 Jul; 82(1):26-34. PubMed ID: 23692281
[TBL] [Abstract][Full Text] [Related]
12. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody CC188 binds a carbohydrate epitope expressed on the surface of both colorectal cancer stem cells and their differentiated progeny.
Xu M; Yuan Y; Xia Y; Achilefu S
Clin Cancer Res; 2008 Nov; 14(22):7461-9. PubMed ID: 19010863
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival.
Hazelbag S; Kenter GG; Gorter A; Dreef EJ; Koopman LA; Violette SM; Weinreb PH; Fleuren GJ
J Pathol; 2007 Jul; 212(3):316-24. PubMed ID: 17503414
[TBL] [Abstract][Full Text] [Related]
15. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E
J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
[TBL] [Abstract][Full Text] [Related]
16. Germinal centre-like versus undifferentiated stromal immunophenotypes in follicular lymphoma.
Chang KC; Huang X; Medeiros LJ; Jones D
J Pathol; 2003 Nov; 201(3):404-12. PubMed ID: 14595752
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of melphalan-DNA adducts in colon cancer cells in vitro and human colorectal liver tumours in vivo.
Rothbarth J; Koevoets C; Tollenaar RA; Tilby MJ; van de Velde CJ; Mulder GJ; Kuppen PJ
Biochem Pharmacol; 2004 May; 67(9):1771-8. PubMed ID: 15081876
[TBL] [Abstract][Full Text] [Related]
18. Characterization of tumour-infiltrating lymphocytes and apoptosis in colitis-associated neoplasia: comparison with sporadic colorectal cancer.
Michael-Robinson JM; Pandeya N; Walsh MD; Biemer-Huttmann AE; Eri RD; Buttenshaw RL; Lincoln D; Clouston AD; Jass JR; Radford-Smith GL
J Pathol; 2006 Feb; 208(3):381-7. PubMed ID: 16315333
[TBL] [Abstract][Full Text] [Related]
19. Influence of cyclical mechanical strain on extracellular matrix gene expression in human lamina cribrosa cells in vitro.
Kirwan RP; Fenerty CH; Crean J; Wordinger RJ; Clark AF; O'Brien CJ
Mol Vis; 2005 Sep; 11():798-810. PubMed ID: 16205625
[TBL] [Abstract][Full Text] [Related]
20. Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma.
Shimo K; Mizuno M; Nasu J; Hiraoka S; Makidono C; Okazaki H; Yamamoto K; Okada H; Fujita T; Shiratori Y
J Gastroenterol Hepatol; 2004 Jun; 19(6):643-7. PubMed ID: 15151618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
